vs
Community West Bancshares（CWBC）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
Community West Bancshares的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.1倍（$38.3M vs $35.5M），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 11.6%），Community West Bancshares自由现金流更多（$43.6M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 36.0%）
Community West Bancshares是一家总部位于美国加利福尼亚州的注册银行控股公司，依据银行控股公司相关法案全资持有Community West Bank，开展银行相关控股经营业务。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
CWBC vs RXRX — 直观对比
营收规模更大
CWBC
是对方的1.1倍
$35.5M
营收增速更快
RXRX
高出670.2%
11.6%
自由现金流更多
CWBC
多$90.9M
$-47.3M
两年增速更快
RXRX
近两年复合增速
36.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $38.3M | $35.5M |
| 净利润 | — | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 40.0% | -304.8% |
| 净利率 | — | -304.2% |
| 营收同比 | 11.6% | 681.7% |
| 净利润同比 | — | 39.6% |
| 每股收益（稀释后） | $0.58 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CWBCRXRX
| Q4 25 | $38.3M | $35.5M | ||
| Q3 25 | $37.9M | $5.2M | ||
| Q2 25 | $35.7M | $19.2M | ||
| Q1 25 | $34.8M | $14.7M | ||
| Q4 24 | $34.3M | $4.5M | ||
| Q3 24 | $31.3M | $26.1M | ||
| Q2 24 | $30.5M | $14.4M | ||
| Q1 24 | $20.7M | $13.8M |
净利润CWBCRXRX
| Q4 25 | — | $-108.1M | ||
| Q3 25 | $10.9M | $-162.3M | ||
| Q2 25 | $7.8M | $-171.9M | ||
| Q1 25 | $8.3M | $-202.5M | ||
| Q4 24 | — | $-178.9M | ||
| Q3 24 | $3.4M | $-95.8M | ||
| Q2 24 | $-6.3M | $-97.5M | ||
| Q1 24 | $3.7M | $-91.4M |
毛利率CWBCRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率CWBCRXRX
| Q4 25 | 40.0% | -304.8% | ||
| Q3 25 | 39.8% | -3327.6% | ||
| Q2 25 | 30.2% | -916.8% | ||
| Q1 25 | 32.7% | -1297.9% | ||
| Q4 24 | 31.0% | -4042.4% | ||
| Q3 24 | 13.3% | -377.1% | ||
| Q2 24 | -25.9% | -697.4% | ||
| Q1 24 | 23.2% | -698.4% |
净利率CWBCRXRX
| Q4 25 | — | -304.2% | ||
| Q3 25 | 28.7% | -3135.3% | ||
| Q2 25 | 22.0% | -894.2% | ||
| Q1 25 | 23.8% | -1373.3% | ||
| Q4 24 | — | -3935.5% | ||
| Q3 24 | 10.8% | -367.5% | ||
| Q2 24 | -20.7% | -676.6% | ||
| Q1 24 | 17.8% | -662.4% |
每股收益（稀释后）CWBCRXRX
| Q4 25 | $0.58 | $-0.17 | ||
| Q3 25 | $0.57 | $-0.36 | ||
| Q2 25 | $0.41 | $-0.41 | ||
| Q1 25 | $0.44 | $-0.50 | ||
| Q4 24 | $0.29 | $-0.56 | ||
| Q3 24 | $0.18 | $-0.34 | ||
| Q2 24 | $-0.33 | $-0.40 | ||
| Q1 24 | $0.31 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $119.0M | $743.3M |
| 总债务越低越好 | $69.5M | $9.6M |
| 股东权益账面价值 | $409.6M | $1.1B |
| 总资产 | $3.7B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.17× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资CWBCRXRX
| Q4 25 | $119.0M | $743.3M | ||
| Q3 25 | $121.6M | $659.8M | ||
| Q2 25 | $134.4M | $525.1M | ||
| Q1 25 | $148.4M | $500.5M | ||
| Q4 24 | $120.4M | $594.4M | ||
| Q3 24 | $149.0M | $427.6M | ||
| Q2 24 | $109.7M | $474.3M | ||
| Q1 24 | $61.0M | $296.3M |
总债务CWBCRXRX
| Q4 25 | $69.5M | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | $69.9M | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益CWBCRXRX
| Q4 25 | $409.6M | $1.1B | ||
| Q3 25 | $397.6M | $1.0B | ||
| Q2 25 | $380.0M | $919.1M | ||
| Q1 25 | $372.2M | $933.9M | ||
| Q4 24 | $362.7M | $1.0B | ||
| Q3 24 | $363.5M | $524.6M | ||
| Q2 24 | $350.2M | $584.4M | ||
| Q1 24 | $211.7M | $401.2M |
总资产CWBCRXRX
| Q4 25 | $3.7B | $1.5B | ||
| Q3 25 | $3.6B | $1.4B | ||
| Q2 25 | $3.6B | $1.3B | ||
| Q1 25 | $3.6B | $1.3B | ||
| Q4 24 | $3.5B | $1.4B | ||
| Q3 24 | $3.5B | $726.5M | ||
| Q2 24 | $3.5B | $775.9M | ||
| Q1 24 | $2.4B | $557.8M |
负债/权益比CWBCRXRX
| Q4 25 | 0.17× | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | 0.19× | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $46.1M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $43.6M | $-47.3M |
| 自由现金流率自由现金流/营收 | 113.9% | -133.1% |
| 资本支出强度资本支出/营收 | 6.6% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $77.7M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流CWBCRXRX
| Q4 25 | $46.1M | $-46.1M | ||
| Q3 25 | $13.2M | $-117.4M | ||
| Q2 25 | $11.5M | $-76.4M | ||
| Q1 25 | $11.1M | $-132.0M | ||
| Q4 24 | $22.2M | $-115.4M | ||
| Q3 24 | $7.8M | $-59.2M | ||
| Q2 24 | $5.2M | $-82.2M | ||
| Q1 24 | $4.0M | $-102.3M |
自由现金流CWBCRXRX
| Q4 25 | $43.6M | $-47.3M | ||
| Q3 25 | $12.8M | $-117.6M | ||
| Q2 25 | $10.6M | $-79.6M | ||
| Q1 25 | $10.8M | $-133.8M | ||
| Q4 24 | $17.2M | $-116.7M | ||
| Q3 24 | $5.2M | $-63.8M | ||
| Q2 24 | $4.8M | $-83.4M | ||
| Q1 24 | $3.6M | $-109.0M |
自由现金流率CWBCRXRX
| Q4 25 | 113.9% | -133.1% | ||
| Q3 25 | 33.7% | -2272.5% | ||
| Q2 25 | 29.6% | -413.9% | ||
| Q1 25 | 30.9% | -907.4% | ||
| Q4 24 | 50.0% | -2567.7% | ||
| Q3 24 | 16.7% | -244.6% | ||
| Q2 24 | 15.7% | -578.5% | ||
| Q1 24 | 17.3% | -789.9% |
资本支出强度CWBCRXRX
| Q4 25 | 6.6% | 3.5% | ||
| Q3 25 | 1.1% | 4.7% | ||
| Q2 25 | 2.7% | 16.4% | ||
| Q1 25 | 0.9% | 12.4% | ||
| Q4 24 | 14.7% | 28.6% | ||
| Q3 24 | 8.1% | 17.5% | ||
| Q2 24 | 1.4% | 8.2% | ||
| Q1 24 | 2.1% | 48.2% |
现金转化率CWBCRXRX
| Q4 25 | — | — | ||
| Q3 25 | 1.21× | — | ||
| Q2 25 | 1.47× | — | ||
| Q1 25 | 1.33× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.29× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.09× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
